Biochemistry and
Biotechnology Professionals
Society of Kenya (BBPSK)
Artificial Intelligence is rapidly transforming therapeutic antibody design, promising to accelerate the transition of drug candidates from the laboratory to clinical trials. However, as these technologies evolve, a critical question remains: How reliable are these models in a real-world biophysical context?
In an upcoming session, Dr. Chungyoun will present findings from the FLAb2 benchmark - the largest public dataset of its kind—to provide a humbling and essential reality check on the current state of AI in biologics.